CoChat
Sign Up
Cited by 200Cardiovascular Disease and AdiposityHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 10 of the 22 sources its claims cite were checked for support.

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

Open access
Kramer, Christopher M., Borlaug, Barry A., Zile, Michael R., Ruff, Dustin, DiMaria, Joseph M., Menon, Venu, Ou, Yang, Zarante, Angela M., Hurt, Karla C., Murakami, Masahiro, Packer, Milton·2025·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2024.11.001
Open this paper in CoChat — free account

Abstract

BACKGROUND: Obesity is a known risk factor for heart failure with preserved ejection fraction (HFpEF) and is considered a distinct phenotype with more concentric remodeling. Epicardial adipose tissue (EAT) is also increased in obesity-related HFpEF and is associated with adverse events. OBJECTIVES: The cardiac magnetic resonance (CMR) substudy of the SUMMIT trial aimed to examine the effects of tirzepatide on cardiac structure and function with the underlying hypothesis that it would reduce left ventricular (LV) mass and EAT in obesity-related HFpEF. METHODS: A total of 175 patients with obesity-related HFpEF from the parent study of tirzepatide (2.5 mg subcutaneously weekly, increasing to a maximum of 15 mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging. A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks. The prespecified primary endpoint of this substudy was between-group changes in LV mass. RESULTS: LV mass decreased by 11 g (95% CI: -19 to -4 g) in the treated group (n = 50) when corrected for placebo (n = 56) (P = 0.004). Paracardiac adipose tissue decreased in the treated group by 45 mL (95% CI: -69 to -22 mL) when corrected for placebo (P < 0.001). The change in LV mass in the treated group correlated with changes in body weight (P < 0.02) and tended to correlate with changes in waist circumference and blood pressure (P = 0.06 for both). The LV mass change also correlated with changes in LV end-diastolic volume and left atrial end-diastolic and end-systolic volumes (P < 0.03 for all). CONCLUSIONS: The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial. (A Study of Tirzepatide [LY3298176] in Participants With Heart Failure With Preserved Ejection Fraction [HFpEF] and Obesity: The SUMMIT Trial; NCT04847557).

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

In the CMR substudy of the SUMMIT trial, tirzepatide reduced left ventricular mass and paracardiac adipose tissue versus placebo in patients with obesity-related HFpEF over 52 weeks. The LV mass reduction paralleled weight loss, suggesting a mechanism that may contribute to the heart failure event reduction seen in the main trial.

Key findings

  • Placebo-corrected LV mass decreased by −11 g (95% CI: −19 to −4 g; P = 0.004) in the tirzepatide group (n = 50) versus placebo (n = 56).
  • Placebo-corrected paracardiac adipose tissue decreased by −45 mL (95% CI: −69 to −22 mL; P < 0.001), driven by pericardial fat (−43 g; 95% CI: −65 to −21 g; P < 0.001); epicardial adipose tissue decreased in both groups with no between-group difference.
  • Between-group difference in stroke volume change was −8 mL (95% CI: −14 to −2 mL; P = 0.011); no between-group differences in end-systolic volume, cardiac output, ejection fraction, LV strain, or LA volumes/function/strain.
  • In the treated group, LV mass change correlated with body weight change (r = 0.34; P < 0.02), LV end-diastolic volume (r = 0.33; P < 0.03), LA end-systolic volume (r = 0.42; P = 0.003), and LA end-diastolic volume (r = 0.50; P < 0.001); it tended to correlate with waist circumference and systolic blood pressure (r = 0.27; P = 0.06 for both).
  • Substudy heart failure outcome events: 3 in tirzepatide (6.0%) vs 8 in placebo (14.2%).

Methods

  • Substudy of the SUMMIT trial (NCT04847557); 175 of 731 parent-trial patients with obesity-related HFpEF (EF ≥50%, BMI ≥30 kg/m², NYHA II–IV) underwent baseline CMR; 106 (50 tirzepatide, 56 placebo) completed baseline and 52-week CMR with adequate image quality.
  • Randomized to tirzepatide (2.5 mg SC weekly titrated to a maximum of 15 mg weekly) or matching placebo; CMR protocol used ECG-gated, breath-held steady-state free precession cine imaging at 1.5-T or 3-T, analyzed at a core laboratory blinded to treatment and timepoint.
  • Prespecified primary endpoint: between-group change in LV mass; analyzed by ANCOVA with baseline measure as covariate and fixed effects for treatment, type 2 diabetes, and baseline BMI group (<35, ≥35 kg/m²); Pearson correlations for associations; no correction for multiple comparisons.

Limitations

  • Stated: 58 of 175 enrollees (33%) had inadequate CMR images for primary endpoint analysis; sites could perform CMR but were not necessarily expert, and obesity complicated gating and breath holding. Excluded/non-imaged patients differed only by country of origin, ethnicity, and minor height and systolic blood pressure differences.
  • Stated: LA volumes were analyzed from biplane long-axis images rather than modified Simpson's method from short-axis stacks, potentially lowering reproducibility; T1 mapping/ECV and late gadolinium enhancement were not performed, so it is unknown whether LV mass reduction reflected reduced cardiomyocyte mass, interstitial fibrosis, or both; right ventricular structure/function were not prespecified.
  • Evident from the text: the substudy was not powered for clinical events (3 vs 8 events reported as a trend), and no corrections were made for multiple comparisons across the many secondary measures analyzed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2024.11.001

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

10 of 22 cited sources checked · 8 supported · 0 flagged · accuracy not yet measured

  • Premisecitation
    § Discussion

    In the echocardiographic analysis from the STEP-HFpEF study, effects of semaglutide on paracardiac fat were not reported.

    “In the echocardiographic analysis from the STEP-HFpEF study, effects of semaglutide on paracardiac fat were not reported.11”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [11] Solomon, 2024, Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure, J Am Coll Cardiol source
  • Findingown data
    § Results

    In the SUMMIT CMR substudy, placebo-corrected LV mass decreased by 11 g (95% CI −19 to −4 g; P=0.004) in tirzepatide-treated patients with obesity-related HFpEF.

    “LV mass decreased by 11 g (95% CI: −19 to −4 g) in the treated group (n = 50) when corrected for placebo (n = 56) (P = 0.004).”
    • Also stated in: § Results · plain
      “The placebo-corrected decline in LV mass was −11 g (95% CI: −19 to −4 g; P = 0.004) (Table 2).”
    Quote in the paperSubstantial claim
  • Findingown data
    § Results

    At baseline, patients with obesity-related HFpEF exhibited increased LA end-systolic volume compared with normal values in the literature.

    “Compared with healthy patients, at baseline, patients with obesity-related HFpEF exhibited an increase in LV mass and LA end-systolic and end-diastolic volumes when compared with normal values in the literature (Supplemental Table 2).”
    Quote in the paperNot a substantial claim
  • Findingown data
    § Results

    There was no between-group difference in LA ejection fraction.

    “There were no between-group differences in LA end-systolic or end-diastolic volumes, ejection fraction, or strain.”
    Quote in the paperNot a substantial claim
  • Findingown data
    § Results

    There was no between-group difference in LA end-systolic volume.

    “There were no between-group differences in LA end-systolic or end-diastolic volumes, ejection fraction, or strain.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim. 26
  • It may state two separate claims as one. 12

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Premisecitation
    § Discussion

    Investigators have demonstrated the ability to use CMR to assess fatty acid composition (saturated vs unsaturated) within EAT, and this may better differentiate HFpEF subtypes and response to therapy than volume alone.

    “Investigators have demonstrated the ability to use CMR to assess fatty acid composition (saturated vs unsaturated) within EAT,23,24 and this may better differentiate HFpEF subtypes and response to therapy than volume alone.”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [23] Shah, 2022, Accelerated fatty acid composition MRI of epicardial adipose tissue: Development and application to eplerenone treatment in a mouse model of obesity-induced coronary microvascular disease, Magn Reson Med source
    • cites [24] Echols, 2024, Fatty acid composition MRI of epicardial adipose tissue: methods and detection of proinflammatory biomarkers in ST-segment elevation myocardial infarction patients, Magn Reson Med source

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation
    § Discussion

    Paracardiac adipose tissue has been hypothesized to act in a paracrine manner, with release of proinflammatory and profibrotic adipocytokines and excess free fatty acids with resultant intramyocardial lipid accumulation and myocardial inflammation and fibrosis.

    “Paracardiac adipose tissue has been hypothesized to act in a paracrine manner, with release of proinflammatory and profibrotic adipocytokines and excess free fatty acids with resultant intramyocardial lipid accumulation and myocardial inflammation and fibrosis.19”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [19] Iacobellis, 2022, Epicardial adipose tissue in contemporary cardiology, Nat Rev Cardiol source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation
    § Discussion

    At baseline, the mean LV mass, volumes and ejection fraction were similar to those of a prior CMR study in a HFpEF population.

    “At baseline, the mean LV mass, volumes and ejection fraction were similar to those of a prior CMR study in a HFpEF population.16”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [16] Nakamori, 2023, Obesity-related differences in pathomechanism and outcomes in patients with HFpEF: a CMR study, JACC Adv source

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation
    § Discussion

    There is also some evidence for intramyocardial steatosis contributing to interstitial fibrosis in HFpEF, especially in women.

    “There is also some evidence for intramyocardial steatosis contributing to interstitial fibrosis in HFpEF, especially in women.22”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [22] Ng, 2024, Sexual dimorphism in the relationships between intramyocardial fat, myocardial fibrosis, and exercise intolerance in heart failure with preserved ejection fraction, Eur J Heart Fail source

  • It may state two separate claims as one.

    Premisecitation
    § Discussion

    Paracardiac adipose tissue in patients with obesity may impair LV relaxation and increase cardiac filling pressures.

    “Paracardiac adipose tissue (epicardial and pericardial adipose tissue) in patients with obesity may also impair LV relaxation20 and increase cardiac filling pressures, owing to increases in extrinsic restraint on the heart in obesity-related HFpEF.2,6,7”
    Quote in the paperSubstantial claim4 of 4 sources checked
    • cites [20] Wu, 2020, Myocardial adipose deposition and the development of heart failure with preserved ejection fraction, Eur J Heart Fail source

      The Fat distribution and HFpEF section (page not provided) reports that epicardial fat correlated with LV diastolic dysfunction parameters in men, but not women, and discusses cardiac dysfunction in obesity. It does not establish the same relationship for pericardial fat or for patients with obesity generally. The filling-pressure and extrinsic-restraint clause is attached to other citations, not this source. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [2] Obokata, 2017, Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction, Circulation source
    • cites [6] Obokata, 2022, Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity, Eur J Heart Fail source
    • cites [7] Koepp, 2020, Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction, JACC Heart Fail source

  • It may state two separate claims as one.

    Findingown data
    § Results

    Pericardial adipose tissue decreased significantly in the tirzepatide-treated group and tended to increase in the placebo group, with a placebo-corrected difference of −43 g (95% CI −65 to −21 g; P<0.001).

    “Pericardial adipose tissue decreased significantly in the treated group and, although not statistically significant, tended to increase in the placebo group, with the placebo-corrected difference of −43 g (95% CI: −65 to −21 g; P < 0.001).”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Findingown data
    § Results

    In the tirzepatide-treated group, the change in LV mass tended to correlate with the change in systolic blood pressure (r=0.27; P=0.06).

    “and although not statistically significant, tended to correlate with change in systolic blood pressure (r = 0.27; P = 0.06).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Findingown data
    § Results

    In the tirzepatide-treated group, the change in LV mass tended to correlate with the change in waist circumference (r=0.27; P=0.06).

    “and although not statistically significant, tended to correlate with waist circumference (r = 0.27; P = 0.06).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Findingcitation
    § Discussion

    In the present study, EAT was lower than that measured in the study by Nakamori et al, whereas paracardiac adipose tissue values were similar to what was termed "EAT" in the latter study.

    “In the present study, EAT was lower than that measured in the study by Nakamori et al,16 whereas paracardiac adipose tissue values were similar to what was termed “EAT” in the latter study.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [16] Nakamori, 2023, Obesity-related differences in pathomechanism and outcomes in patients with HFpEF: a CMR study, JACC Adv source

      Checked before — its earlier verdict is held back until a new check runs.

  • It may state two separate claims as one.

    Findingown data
    § Results

    Epicardial adipose tissue decreased in both tirzepatide and placebo groups, with no between-group differences.

    “EAT decreased in both groups, with no differences between them.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Findingown data
    § Results

    At baseline, there was 4-fold more pericardial adipose tissue than epicardial adipose tissue in both groups.

    “At baseline, there was 4-fold more pericardial adipose tissue than EAT in both groups (Table 2).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation
    § Discussion

    A recent randomized study using noncontrast computed tomography in the STOP trial showed semaglutide reduced EAT by 19.3 mm3 as compared with placebo in 115 diabetic patients with known coronary artery disease.

    “A recent randomized study using noncontrast computed tomography in a prespecified secondary analysis of the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) trial, the GLP-1 RA semaglutide was shown to reduce EAT by 19.3 mm3 as compared with placebo in 115 diabetic patients with known coronary artery disease.21”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [21] Manubolu, 2024, Effect of semaglutide on epicardial adipose tissue in type 2 diabetes, J Am Coll Cardiol source

      Checked before — its earlier verdict is held back until a new check runs.

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Premisecitation
    § Discussion

    In the meta-analysis of studies of GLP-1 RA in diabetes, LA volume decrease of 8 mL was similar to that noted in the present study, but no change was noted in LV end-diastolic volume.

    “In the meta-analysis of studies of GLP-1 RA in diabetes discussed previously, LA volume decrease of 8 mL was similar to that noted in the present study, but no change was noted in LV end-diastolic volume.9”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [9] Zhang, 2024, The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis, Diabetes Obes Metab source

  • Probably not a substantial claim. It may be too vague to check against evidence.

    Interpretationown data
    § Discussion

    This finding demonstrates the power of CMR to differentiate these 2 fat depots.

    “This finding demonstrates the power of CMR to differentiate these 2 fat depots.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. It may state two separate claims as one.

    Study design and conductnone given
    § Methods

    All hypothesis testing was performed at the 0.05 significance level with no corrections made for multiple comparisons across the multiple different measure analyses.

    “All hypothesis testing was performed at the 0.05 significance level with no corrections made for multiple comparisons across the multiple different measure analyses.”
    Quote in the paperSubstantial claim

  • It may state two separate claims as one.

    Study design and conductown data
    § Results

    No differences were noted between groups at baseline, neither for the 175 who enrolled nor for the 106 who completed.

    “No differences were noted between groups at baseline, neither for the 175 who enrolled (Supplemental Table 1) nor for the 106 who completed.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.

    Study design and conductnone given
    § Discussion

    LA volumes were analyzed from biplane long-axis images rather than a modified Simpson's method from stacks of short-axis images, which may lead to lower reproducibility.

    “LA volumes were analyzed from biplane long-axis images rather than a modified Simpson’s method from stacks of short-axis images, which may lead to lower reproducibility.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductnone given
    § Discussion

    Late gadolinium enhancement imaging was not performed.

    “In addition, late gadolinium enhancement imaging was not performed”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Study design and conductnone given
    § Methods

    The ethics committee at each investigative site approved the trial, and all patients provided written informed consent.

    “The ethics committee at each investigative site approved the trial, and all patients provided written informed consent.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.

    Interpretationnone given
    § Discussion

    Tirzepatide may have an effect on EAT biology that cannot be discerned by CMR.

    “but tirzepatide may have an effect on EAT biology that cannot be discerned by CMR.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation
    § Discussion

    Echocardiographically estimated LV filling pressures have been shown to improve with GLP-1 RA in HFpEF, as shown in the STEP-HFpEF echocardiographic substudy.

    “Echocardiographically estimated LV filling pressures have been shown to improve with GLP-1 RA in HFpEF, as shown in the STEP-HFpEF echocardiographic substudy with improved E-wave velocity, early/late mitral inflow velocity ratio, and early mitral inflow velocity/early diastolic mitral annular velocity.11”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [11] Solomon, 2024, Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure, J Am Coll Cardiol source

      Checked before — its earlier verdict is held back until a new check runs.

  • Probably not a substantial claim.

    Study design and conductnone given
    § Methods

    The prespecified primary endpoint of this substudy was between-group changes in LV mass.

    “The prespecified primary endpoint of this substudy was between-group changes in LV mass.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductreasoning
    § Discussion

    A total of 58 (33%) of 175 enrollees had inadequate CMR images for analysis of the primary endpoint despite a straightforward protocol.

    “A total of 58 (33%) of 175 enrollees had inadequate CMR images for analysis of the primary endpoint despite a straightforward protocol.”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Premisecitation
    § Discussion

    CMR has improved interstudy reproducibility compared with echocardiography, allowing significantly smaller sample sizes for clinical trials seeking changes in LV mass.

    “Prior studies show that, due to improved interstudy reproducibility of CMR, sample sizes for clinical trials that seek to look for changes in LV mass can be significantly smaller as compared with echocardiography.17”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [17] Grothues, 2002, Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy, Am J Cardiol source

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductnone given
    § Discussion

    Right ventricular structure and function were not prespecified analyses in the present study.

    “Right ventricular structure and function were not prespecified analyses in the present study.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim.

    Study design and conductnone given
    § Methods

    The same scanner was used at baseline and follow-up imaging.

    “The same scanner was used at baseline and follow-up imaging.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.

    Interpretationnone given
    § Discussion

    The effect on pericardial fat reflects the effect of tirzepatide on visceral fat.

    “The effect on pericardial fat reflects the effect of tirzepatide on visceral fat.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductnone given
    § Discussion

    Care was taken in the present study to meticulously differentiate epicardial and pericardial adipose tissue using the visceral pericardial layer as a landmark.

    “Care was taken in the present study to meticulously differentiate epicardial and pericardial adipose tissue using the visceral pericardial layer as a landmark.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductreasoning
    § Discussion

    T1 mapping to measure ECV was not performed as part of the CMR protocol, largely due to its complexity in a multicenter international trial.

    “T1 mapping to measure ECV was not performed as part of the CMR protocol, largely due to its complexity in a multicenter international trial.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Premisecitation
    § Discussion

    LA diameter, but not volumes, was measured in the latter study, so no comparison can be made.

    “LA diameter, but not volumes, was measured in the latter study, so no comparison can be made.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [16] Nakamori, 2023, Obesity-related differences in pathomechanism and outcomes in patients with HFpEF: a CMR study, JACC Adv source

      Checked before — its earlier verdict is held back until a new check runs.

  • Probably not a substantial claim.

    Study design and conductnone given
    § Methods

    An image analyst with 25 years of experience performed image analysis blinded to the treatment group and time of image acquisition.

    “An image analyst (J.M.D.) with 25 years of experience performed image analysis blinded to the treatment group and time of image acquisition.”
    Quote in the paperSubstantial claim
31 of 31

  • The paper relies on this without support.

    There is a paucity of data regarding the relationship between reduction in LV mass and improved outcomes in HFpEF.

    “There is a paucity of data with regard to reduction in LV mass and improved outcomes in HFpEF.”
1 of 1

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., & Packer, M.
Affiliations
  • University of Virginia Health System (US)
  • Mayo Clinic (US)
  • Medical University of South Carolina (US)
  • Eli Lilly (United States) (US)
  • Cleveland Clinic (US)
  • Baylor University Medical Center (US)
Corresponding author
Kramer, Christopher M.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2025-02
Volume
85
Issue
7
Pages
699-706
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2024.11.001
OpenAlex
W4404470149
Cited by
200
References
25
Citations by year
2026: 97 · 2025: 101
FWCI
56.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
heart failure with preserved ejection fraction, left ventricular mass, epicardial adipose tissue, cardiac magnetic resonance, weight loss, left atrial volume, SUMMIT trial, GLP-1 receptor agonists, cardiac remodeling, blood pressure, waist circumference, left ventricular function
MeSH terms
Tirzepatide, Adipose Tissue, Aged, Double-Blind Method, Female, Heart Failure, Heart Ventricles, Humans, Male, Middle Aged, Obesity, Stroke Volume, Magnetic Resonance Imaging, Cine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review